FBXO25

FBXO25 is a nuclear F-box protein that serves as the substrate-recognition subunit of an SCF-type (Skp1–Cul1–Roc1) E3 ubiquitin ligase, assembling through an atypical serine residue in its F-box domain that mediates Skp1 binding (PMID:16278047, PMID:16714087). The assembled SCF(FBXO25) complex is catalytically active and directs ubiquitin-dependent proteasomal turnover of a range of nuclear and signaling substrates. In the apoptotic program, PRKCD (PKCδ) phosphorylates both FBXO25 and the pro-survival protein HAX-1, redirecting nuclear FBXO25 to ubiquitinate and degrade HAX-1; monoallelic FBXO25 loss and stabilizing HAX1 phosphodegron mutations occur in mantle cell lymphoma, where FBXO25 re-expression promotes cell death and its knockdown accelerates Eμ-Myc-driven lymphoma, defining FBXO25 as a haploinsufficient tumor suppressor (PMID:25419709). FBXO25 also targets cardiac transcription factors Nkx2-5, Isl1, Hand1, and Tbx5 for ubiquitination and degradation, thereby tuning cardiomyocyte differentiation (PMID:21596019, PMID:25725482), and promotes H2BK120 mono-ubiquitination to drive osteogenic gene expression, with its own levels controlled by lncRNA ODIR1-directed CUL3-dependent degradation (PMID:31827076). FBXO25 negatively regulates MAPK/ERK signaling by suppressing ERK1/2 phosphorylation independently of MEK1/2 (PMID:28389297). The protein concentrates in dynamic subnuclear FBXO25-associated nuclear domains (FAND) containing ubiquitin conjugates, 20S proteasome, and Skp1; these structures are dependent on ongoing transcription and on nuclear β-actin organization, and FBXO25 ligase activity prevents nuclear polyglutamine huntingtin aggregation (PMID:18287534, PMID:20473970). A prior assignment of ELK-1 as an FBXO25 substrate was contradicted by a replication study that confirmed FBXO25–ELK-1 interaction but found no ELK-1 ubiquitination or degradation (PMID:23940030, PMID:33428929).

1. 2005 Medium

   Establishing whether FBXO25 is a bona fide F-box protein defined its molecular identity as an SCF ligase adaptor rather than an orphan nuclear protein.

   Evidence Co-IP with Skp1/Cul1 and F-box serine mutagenesis, with nuclear localization and brain expression by immunochemistry and RT-PCR

   PMID:16278047

   Open questions at the time

   • No substrate identified at this stage
   • Functional ligase activity not yet demonstrated
2. 2006 Medium

   Demonstrating that FBXO25 assembles a productive SCF complex with in vitro ligase activity confirmed it is an enzymatically functional ligase, distinct in tissue and atrophy regulation from its paralog atrogin-1.

   Evidence Co-IP plus in vitro ubiquitin ligase assay; RT-PCR tissue panel; mouse fasting/dexamethasone/diabetes muscle-atrophy models

   PMID:16714087

   Open questions at the time

   • No physiological substrate identified
   • Activity shown only in vitro
3. 2008 Medium

   Identifying that FBXO25 concentrates in transcription-sensitive subnuclear FAND containing proteasome and ubiquitin conjugates placed its activity in a defined nuclear compartment and linked it to protein-aggregation control.

   Evidence Confocal immunofluorescence, biochemical fractionation, actinomycin D/heat-shock perturbation, and huntingtin aggregation assay in HEK293

   PMID:18287534

   Open questions at the time

   • Molecular function of FAND undefined
   • Endogenous substrate degraded in FAND not identified
4. 2010 Medium

   Mapping the FBXO25 interactome and the β-actin dependence of FAND connected its compartmentalization to nuclear actin and transcriptional machinery.

   Evidence Two-step affinity purification MS, two-hybrid screen, β-actin co-IP, actin polymerization inhibitors, in vitro RNA Pol II transcription assay

   PMID:20473970

   Open questions at the time

   • 132 candidate partners mostly unvalidated
   • Direct ubiquitination substrates among partners not established
5. 2011 Medium

   Identifying cardiac transcription factors as direct substrates assigned FBXO25 a developmental role in regulating cardiomyocyte transcription factor abundance.

   Evidence Ubiquitination assays, MG132 rescue, immunofluorescence, and immunoblot in cardiomyocytes and ESC differentiation model

   PMID:21596019

   Open questions at the time

   • In vivo cardiac requirement not tested by genetic loss
   • Recruitment determinants/degrons on substrates undefined
6. 2013 Medium

   Assigning ELK-1 as an SCF(FBXO25) substrate proposed a role in dampening immediate-early MAPK target gene induction.

   Evidence Protein microarray ubiquitination screen, co-IP, ubiquitination assay, cycloheximide chase, and RT-PCR in HEK293T

   PMID:23940030

   Open questions at the time

   • Later contradicted for ELK-1 ubiquitination
   • Endogenous-level effects not established
7. 2014 High

   Defining the PRKCD–FBXO25–HAX-1 axis explained how an apoptotic kinase signal is converted into degradation of a survival factor, and established FBXO25 as a haploinsufficient tumor suppressor in mantle cell lymphoma.

   Evidence Unbiased substrate screen, co-IP, ubiquitination and PRKCD phosphorylation assays, genomic deletion mapping in human MCL, re-expression/knockdown in MCL lines, and Eμ-Myc and xenotransplant mouse models

   PMID:25419709

   Open questions at the time

   • Structural basis of phospho-directed nuclear-to-mitochondrial substrate handoff unresolved
   • Full substrate spectrum in lymphoma not defined
8. 2015 Medium

   Extending substrate degradation to Tbx5 and Nkx2-5 with a dominant-negative mutant established that FBXO25 ubiquitin-proteasome activity restrains cardiac transcription factor activity during cardiomyocyte differentiation.

   Evidence Co-IP, MG132 rescue, ts20 temperature-sensitive ubiquitin system, dominant-negative mutant, luciferase reporter, siRNA, mESC/hESC differentiation and myocardial infarction models

   PMID:25725482

   Open questions at the time

   • In vivo developmental phenotype of FBXO25 null heart not shown
   • Regulation of FBXO25 activity in cardiac context unclear
9. 2017 Medium

   Showing FBXO25 loss enhances PMA-induced ERK1/2 phosphorylation independently of MEK1/2 placed FBXO25 as a negative regulator of MAPK/ERK output and proliferation.

   Evidence FBXO25 overexpression and KO HAP1 cells, phospho-ERK1/2 immunoblot, PMA stimulation, proliferation assay

   PMID:28389297

   Open questions at the time

   • Direct ubiquitination substrate mediating ERK suppression not identified
   • MEK-independent mechanism undefined
10. 2019 Medium

    Linking FBXO25 to H2BK120 mono-ubiquitination and its own ODIR1/CUL3-directed degradation connected FBXO25 to chromatin-based control of osteogenic transcription and revealed a layer of post-translational regulation of FBXO25 itself.

    Evidence RNA-IP, co-IP, ChIP, ubiquitination assay, siRNA/overexpression in hUC-MSCs, and in vitro/in vivo osteogenic differentiation

    PMID:31827076

    Open questions at the time

    • Mechanism by which FBXO25 promotes H2BK120ub (direct vs indirect) unclear
    • Generality beyond OSX locus untested
11. 2020 Medium

    A direct replication corrected the substrate record by confirming FBXO25–ELK-1 binding but excluding ELK-1 as a degradation substrate, sharpening the bona fide substrate set.

    Evidence Co-IP, ubiquitination assay, protein turnover assay, RNAi, and gene expression analysis in HEK293T

    PMID:33428929

    Open questions at the time

    • Functional consequence of the retained ELK-1 interaction unknown
    • Does not address other proposed substrates
12. 2020 Low

    Identifying an FBXO25–Oct-1–cyclin D1 axis proposed a context-dependent tumor-promoting role in cutaneous squamous cell carcinoma, contrasting its tumor-suppressor role in lymphoma.

    Evidence FBXO25 knockdown/overexpression in SCC13 cells, FBXO25–Oct-1 co-IP, in vivo tumor growth, and cyclin D1 rescue

    PMID:32335130

    Open questions at the time

    • Single Co-IP without reciprocal/ubiquitination validation of Oct-1 as substrate
    • Tissue-context basis for opposite cancer roles unexplained

• How a single nuclear SCF(FBXO25) adaptor selects among diverse substrates across apoptotic, cardiac, osteogenic, and signaling contexts — and how upstream signals and FAND localization gate this selection — remains unresolved.
• No structural model of substrate or degron recognition
• Determinants of context-specific substrate choice unknown
• Physiological loss-of-function phenotype across tissues not defined